Dr. Irina L. Gurevich, MD

Dr. Gurevich practices at Beth Israel Deaconess Hospital-Plymouth in Plymouth, Massachusetts, part of Beth Israel Lahey Health.

Dr. Gurevich's NPI, 1013995992, was assigned on January 3, 2006. Dr. Gurevich holds Massachusetts license 152492.

Dr. Gurevich's primary practice is Beth Israel Deaconess Hospital-Plymouth, at 275 Sandwich Street, Plymouth, MA 02360 in Plymouth County. The practice phone is (508) 746-2000.

Dr. Gurevich's primary practice is Beth Israel Deaconess Hospital-Plymouth in Plymouth, Massachusetts, part of Beth Israel Lahey Health. Dr. Gurevich is also affiliated with Beth Israel Deaconess Medical Center. The medical group on file is Beth Israel Deaconess Hospital-Plymouth (BID-Plymouth). Dmand AI also links Dr. Gurevich to 1 more hospital, 1 hospice and 1 imaging center, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Gurevich practices, 5 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Gurevich's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Gurevich is licensed in Massachusetts.

CMS data shows 1,154 Medicare services from Dr. Gurevich across 11 procedure codes in 2024, for 429 Medicare patients. Medicare paid $77,901 for them.

CMS counts 429 Medicare patients who saw Dr. Gurevich in 2024. The largest group is 75 to 84, with 183 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 18% are also on Medicaid. Their average risk score is 1.91, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Gurevich's median patient age at 75, with 70% women.

In 2024, Dr. Gurevich wrote 1,598 Medicare Part D claims for 241 patients. 81% of them were for generic drugs. CMS names the drug for 1,316 of them, across 42 drugs with 11 or more claims each, at $1,561,447 in total drug cost. In 2023, CMS named 1,272 claims across 41 drugs.

Dr. Gurevich accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Gurevich as offering telehealth.

Dmand AI links 13 papers to Dr. Gurevich, published from 2011 to 2024. 2013 was the busiest year, with 2. The most frequent topics are Cell Movement, Dendritic Cells and Mice, Inbred C57BL. Dr. Gurevich has published most often in Eur J Immunol. Dr. Gurevich's most frequent co-authors are Paul Laszlo Bollyky, MD, PhD, Payton Marshall and Pooja Agarwal Agarwal, MD.

CMS Open Payments shows 21 general payments to Dr. Gurevich from 11 drug and device companies from 2016 to 2021. Food and beverage make up the largest share, 95% of the total. Genentech, Inc. paid the most, $150.